{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:05:04Z","timestamp":1777529104483,"version":"3.51.4"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1656,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The number of patients receiving sodium\u2013glucose cotransporter 2 inhibitors (SGLT2is), especially those with heart failure, is increasing worldwide. SGLT2is control glycaemia by triggering glycosuria with simultaneous facilitation of a more ketogenic metabolic profile. Patients therefore are more prone to develop euglycaemic diabetic ketoacidosis (euDKA), an entity largely unknown beyond diabetes care professionals. We present a heart failure with preserved ejection fraction (HFpEF) patient with known Type 2 diabetes. He was treated with dapagliflozin and presented acutely with dyspnoea, hyperglycaemia, and ketoacidosis. After standard treatment for diabetic ketoacidosis, hyperglycaemia was corrected, while metabolic ketoacidosis persisted, and thus, euDKA was suspected. With adequate therapy, the patient recovered completely and was discharged without any sequelae. To the best of our knowledge, our case is the first to describe SGLT2i-induced euDKA in HFpEF patients. Regarding no previous reports of euDKA in heart failure with reduced ejection fraction, our report is highly relevant for ongoing SGLT2i trials in HFpEF and clinical practice in general.<\/jats:p>","DOI":"10.1002\/ehf2.13452","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T05:30:42Z","timestamp":1623216642000},"page":"2631-2636","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sodium\u2013Glucose Cotransporter 2 Inhibitor-Induced Euglycaemic Diabetic Ketoacidosis in Heart Failure with Preserved Ejection Fraction"],"prefix":"10.1093","volume":"8","author":[{"given":"Luka","family":"Cavka","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Institute of Oncology Ljubljana , Zalo\u0161ka cesta 2, Ljubljana, 1000 ,","place":["Slovenia"]},{"name":"Department of Oncology, University Medical Center Maribor , Maribor ,","place":["Slovenia"]},{"name":"Division of Cardiology, General Hospital Murska Sobota , Murska Sobota ,","place":["Slovenia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urska","family":"Bencak Ferko","sequence":"additional","affiliation":[{"name":"Division of Cardiology, General Hospital Murska Sobota , Murska Sobota ,","place":["Slovenia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasa","family":"Pitz","sequence":"additional","affiliation":[{"name":"Division for Diabetes, General Hospital Murska Sobota , Murska Sobota ,","place":["Slovenia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoranco","family":"Trpkovski","sequence":"additional","affiliation":[{"name":"Division for Diabetes, General Hospital Murska Sobota , Murska Sobota ,","place":["Slovenia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitja","family":"Lainscak","sequence":"additional","affiliation":[{"name":"Division of Cardiology, General Hospital Murska Sobota , Murska Sobota ,","place":["Slovenia"]},{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana ,","place":["Slovenia"]},{"name":"Faculty of Natural Sciences and Mathematics, University of Maribor , Maribor ,","place":["Slovenia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"2026012114214897900_ehf213452-bib-0001","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2019.03.014","article-title":"Euglycemic diabetic ketoacidosis","volume":"63","author":"Barski","year":"2019","journal-title":"Eur J Intern Med"},{"key":"2026012114214897900_ehf213452-bib-0002","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00592-020-01538-0","article-title":"Multicentre analysis of hyperglycaemic hyperosmolar state and diabetic ketoacidosis in type 1 and type 2 diabetes","volume":"57","author":"Tittel","year":"2020","journal-title":"Acta Diabetol"},{"key":"2026012114214897900_ehf213452-bib-0003","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.2337\/dc17-1721","article-title":"SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications","volume":"41","author":"Meyer","year":"2018","journal-title":"Diabetes Care"},{"key":"2026012114214897900_ehf213452-bib-0004","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/dom.14075","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Liu","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026012114214897900_ehf213452-bib-0005","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/bmj.2.5866.578","article-title":"Euglycaemic diabetic ketoacidosis","volume":"2","author":"Munro","year":"1973","journal-title":"Br Med J"},{"key":"2026012114214897900_ehf213452-bib-0006","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012114214897900_ehf213452-bib-0007","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012114214897900_ehf213452-bib-0008","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114214897900_ehf213452-bib-0009","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium\u2013glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114214897900_ehf213452-bib-0010","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114214897900_ehf213452-bib-0011","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012114214897900_ehf213452-bib-0012","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/ejhf.2065","article-title":"Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114214897900_ehf213452-bib-0013","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1002\/ehf2.12891","article-title":"Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME","volume":"7","author":"Pellicori","year":"2020","journal-title":"ESC Heart Failure"},{"key":"2026012114214897900_ehf213452-bib-0014","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s13300-020-00911-0","article-title":"Dapagliflozin for heart failure with preserved ejection fraction: will the DELIVER study deliver?","volume":"11","author":"Williams","year":"2020","journal-title":"Diabetes Ther"},{"key":"2026012114214897900_ehf213452-bib-0015","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ejhf.1954","article-title":"Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114214897900_ehf213452-bib-0016","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ehf2.12505","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions","volume":"6","author":"Lan","journal-title":"ESC Heart Fail"},{"key":"2026012114214897900_ehf213452-bib-0017","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ehf2.12617","article-title":"Prescription patterns of diabetes medications influencing clinical outcomes of heart failure patients with reduced ejection fraction","volume":"7","author":"Chang","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114214897900_ehf213452-bib-0018","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012114214897900_ehf213452-bib-0019","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/ejhf.890","article-title":"Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012114214897900_ehf213452-bib-0020","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.xkme.2019.12.006","article-title":"SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report","volume":"2","author":"Wang","year":"2020","journal-title":"Kidney Med"},{"key":"2026012114214897900_ehf213452-bib-0021","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"2026012114214897900_ehf213452-bib-0022","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11892-020-01307-x","article-title":"Euglycemic ketoacidosis","volume":"20","author":"Bonora","year":"2020","journal-title":"Curr Diab Rep"},{"key":"2026012114214897900_ehf213452-bib-0023","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026012114214897900_ehf213452-bib-0024","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/jdi.12473","article-title":"Renal threshold for glucose reabsorption predicts diabetes improvement by sodium-glucose cotransporter 2 inhibitor therapy","volume":"7","author":"Osaki","year":"2016","journal-title":"J Diabetes Investig"},{"key":"2026012114214897900_ehf213452-bib-0025","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.REV120.008387","article-title":"Sodium-glucose cotransporter-2 inhibitors: understanding the mechanisms for therapeutic promise and persisting risks","author":"Perry","year":"2020","journal-title":"J Biol Chem"},{"key":"2026012114214897900_ehf213452-bib-0026","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc16-2724","article-title":"Renal handling of ketones in response to sodium\u2013glucose cotransporter 2 inhibition in patients with type 2 diabetes","volume":"40","author":"Ferrannini","year":"2017","journal-title":"Diabetes Care"},{"key":"2026012114214897900_ehf213452-bib-0027","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors","volume":"7","author":"Ogawa","year":"2016","journal-title":"J Diabetes Investig"},{"key":"2026012114214897900_ehf213452-bib-0028","article-title":"Euglycemic diabetic ketoacidosis in a patient with cocaine intoxication","volume":"2016","author":"Abu-Abed Abdin","year":"2016","journal-title":"Case Rep Crit Care"},{"key":"2026012114214897900_ehf213452-bib-0029","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00228-014-1786-7","article-title":"Drug-drug interaction software in clinical practice: a systematic review","volume":"71","author":"Roblek","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"2026012114214897900_ehf213452-bib-0030","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12030268","article-title":"Comparative pharmacokinetics and pharmacodynamics of a novel sodium-glucose cotransporter 2 inhibitor, DWP16001, with dapagliflozin and ipragliflozin","volume":"12","author":"Choi","year":"2020","journal-title":"Pharmaceutics"},{"key":"2026012114214897900_ehf213452-bib-0031","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.pcd.2017.04.004","article-title":"Dapagliflozin therapy for type 2 diabetes in primary care: changes in HbA1c, weight and blood pressure over 2 years follow-up","volume":"11","author":"Wilding","year":"2017","journal-title":"Prim Care Diabetes"},{"key":"2026012114214897900_ehf213452-bib-0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinane.2021.110201","article-title":"Perioperative euglycemic diabetic ketoacidosis following use of SGLT-2 inhibitors after cardiac surgery","volume":"71","author":"Pontes","year":"2021","journal-title":"J Clin Anesth"},{"key":"2026012114214897900_ehf213452-bib-0033","article-title":"Intraoperative diagnosis of sodium-glucose cotransporter 2 inhibitor-associated euglycemic diabetic ketoacidosis: a case report","volume":"15","author":"Seger","year":"2021","journal-title":"A A Pract"},{"key":"2026012114214897900_ehf213452-bib-0034","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ijscr.2020.11.037","article-title":"Sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis complicating the perioperative management of a patient with type 2 diabetes mellitus (T2DM) and Fournier's gangrene: a case report","volume":"77","author":"Lindsay","year":"2020","journal-title":"Int J Surg Case Rep"},{"key":"2026012114214897900_ehf213452-bib-0035","first-page":"10","article-title":"Euglycemic diabetic ketoacidosis with COVID-19 infection in patients with type 2 diabetes taking SGLT2 inhibitors","volume":"7","author":"Vitale","year":"2021","journal-title":"AACE Clin Case Rep"},{"key":"2026012114214897900_ehf213452-bib-0036","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc09-9032","article-title":"Hyperglycemic crises in adult patients with diabetes","volume":"32","author":"Kitabchi","year":"2009","journal-title":"Diabetes Care"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13452","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13452","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/4\/2631\/65568601\/eschf_8_4_2631.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/4\/2631\/65568601\/eschf_8_4_2631.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:26:53Z","timestamp":1769023613000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/4\/2631\/8344478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,6,8]]},"published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13452","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8]]},"published":{"date-parts":[[2021,6,8]]},"assertion":[{"value":"2021-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}